Razelle Kurzrock, Founding Director of Michels Rare Cancers Research Laboratories at the Medical College of Wisconsin and Co-Founder and Board Member at CureMatch, shared a post on X about a paper he co-authored with colleagues published in Cancer Research:
“Just out. Pancreatic cancers with KRA G12R can respond to MeK inhibitors: dissecting the mechanisms.”
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared this post, adding:
“Unlike the G12C mutation, which has a cysteine residue that can be targeted by covalent inhibitors, G12R lacks this specific residue, requiring different approaches.
Very interesting idea for KRAS G12R mutations.”
Title: Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
Authors: Mandana Kamgar, G. Aaron Hobbs, Raven Davidson, Daniel Dorbin, Juliannie Herrera, John F. Langenheim, Rachel A. Burge, Mohammed Aldakkak, Ryan D. Conrardy, Aniko Szabo, Sam Z. Thalji, Bradley Mayer, Justin J. Grahl, Brian Y. Chung, Alexandria Phan, James P. Thomas, Y. David Seo, Douglas B. Evans, Kathleen K. Christians, Beth Erickson, William Hall, Ben George, Susan Tsai, Nikki K. Lytle, Channing J. Der, Razelle Kurzrock, Thomas McFall
Read the Full Article on Cancer Research.
More posts featuring Razelle Kurzrock on OncoDaily.